The HYPIC trial demonstrates that hydroxychloroquine combined with prednisolone significantly improves cardiovascular outcomes, cardiac function, and cytokine profiles in patients with chronic inflammatory cardiomyopathy following fulminant myocarditis, establishing a novel evidence-based therapeutic strategy.